The Biotechnology Company, Nimbus Therapeutics raises $43M

What does Nimbus do?

Nimbus Therapeutics, is a biotechnology company which focuses on designing highly selective and potent medicines. Formerly called as the Nimbus Discovery, it reflects our transition into a clinical stage company. It is headquartered in Cambridge, Mass, pioneers in a new computational technology driven paradigm for rapid advancement of diverse pipeline of novel small molecule product candidates into clinical development.

The biotech company is designing highly selective and potent medicines for disrupting the known drivers of serious diseases, which includes cancers, immune inflammatory disorders and metabolic syndromes.

How much Nimbus Therapeutics was funded?

Nimbus Therapeutics has raised $43 M in Series B funding on March 18^th, 2015 from Bill Gates, Atlas Venture, Lightstone Ventures, GlaxoSmithKline and Lilly Ventures .

Previous funding

• $3.5Min Venture funding on Apr 29^th, 2010.
• $1.5M in Seed funding on Mar 10th, 2011 from Atlas Venture, Bill Gates and Richard Friesner
• $24M in Series A funding on Jun 28th, 2011 from SR One, Atlas Venture and Lily Ventures

What is next for Nimbus Therapeutics?

The biotech company has changed its name from Nimbus Discovery to Nimbus Therapeutics after it has announced its Series B funding news. It signaled its transition to a clinical stage company.Tthe latest round of funding has set the foundational stage for many key reflection points for Nimbus in this year for years ahead.

The funds are to be used to advance Nimbus Therapeutics lead program, the ACC inhibitor, into clinical development which is intended to treat Non-alcoholic Steatoheapatitis. Also the company is to advance its preclinical programs for medically important targets.

More about Nimbus

Nimbus Therapeutics was founded in 2009 with headquarters in Cambridge, Mass. The company focuses on metabolic diseases, cancer and immune-inflammatory disorders. Using a unique approach and technological capabilities, it is progressing rapidly the highly selective and potent small molecules via development and discovery.